World-First Brain-Targeting Exosome Platform Delivers Curcumin Across Blood-Brain Barrier for Parkinson's Disease
核心洞察
China Medical University Hospital and Ever Supreme Bio Technology (搜索) have developed αDAT-EV, the world's first actively navigated brain-targeting exosome platform capable of transporting therapeutic agents across the blood-brain barrier.
The platform uses genetic engineering to modify exosome surfaces with antibody fragments that recognize dopamine transporter (搜索) (DAT), enabling precise targeting of dopaminergic neurons affected in Parkinson's disease (搜索).
Preclinical studies demonstrate the platform successfully delivers curcumin to key brain regions, activates cellular repair mechanisms, and improves motor function in Parkinson's disease (搜索) animal models.
China Medical University Hospital (CMUH) has announced a major breakthrough in exosome-based drug delivery, developing the world's first actively navigated brain-targeting exosome platform capable of crossing the blood-brain barrier to treat Parkinson's disease (搜索). The research, conducted in collaboration with Ever Supreme Bio Technology (搜索) and Shine-On Biomedical (搜索), has been published in the Journal of Nanobiotechnology.
Revolutionary Platform Overcomes Blood-Brain Barrier Challenge
The αDAT-EV platform addresses a fundamental challenge in neurological medicine: nearly 98% of drugs fail to effectively cross the blood-brain barrier, severely limiting treatment efficacy. Dr. Cho Der-Yang, Superintendent of CMUH, noted that as global populations age, the prevalence of neurodegenerative diseases (搜索) such as Parkinson's disease (搜索) continues to rise sharply.
CMUH researchers employed genetic engineering techniques to modify antibody fragments on the surface of exosomes that recognize the dopamine transporter (搜索) (DAT). This innovation enables αDAT-EVs to actively identify and target dopaminergic neurons, effectively equipping therapeutic agents with a GPS-like navigation system that directs them to diseased brain regions while improving the bioavailability of small-molecule drugs.
Curcumin Delivery Demonstrates Therapeutic Potential
The platform has been tested with curcumin, a compound known for its antioxidant and anti-inflammatory properties. Academician Dr. Lin Jaung-Geng of Academia Sinica explained that despite curcumin's ability to repair neuronal damage and clear pathological protein aggregates, its benefits have historically been "visible but unattainable" due to poor water solubility, rapid metabolism, and inability to cross the blood-brain barrier.
Through the αDAT-EV brain-targeting platform, curcumin can now be actively guided into the brain, functioning as a modern nano-scale medicinal guide. This breakthrough exemplifies the integration of traditional medical wisdom with cutting-edge biotechnology.
Preclinical Studies Show Multi-Pathway Cellular Repair
According to Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology (搜索), preclinical studies using αDAT-EVs loaded with curcumin have demonstrated promising therapeutic effects in both cellular and animal models:
Precision Targeting: The platform significantly enhances drug penetration across the blood-brain barrier and enriches therapeutic agents in key Parkinson's disease (搜索)-related regions, including the substantia nigra and ventral tegmental area.
Activation of Repair Mechanisms: αDAT-EVs trigger cellular autophagy-lysosomal pathways and mitochondrial repair mechanisms, effectively clearing pathological α-synuclein (搜索) aggregates and alleviating disease symptoms.
Immune Modulation: The treatment promotes a shift in brain microglia from a pro-inflammatory to a reparative phenotype, indicating reduced neuroinflammation.
Improved Motor Function: Parkinson's disease (搜索) animal models exhibited marked recovery in motor coordination, underscoring the platform's strong clinical translation potential.
Versatile Platform Expands CNS Therapeutic Applications
The αDAT-EV brain-targeting exosome platform is highly scalable and expandable. While initially developed to deliver cytotoxic payloads against cancer cells, it now demonstrates the ability to transport therapeutic agents for neuronal repair. The platform may be adapted to deliver small-molecule drugs, nucleic acid therapies (mRNA), or protein-based therapeutics, with potential applications in Alzheimer's disease (搜索), stroke (搜索), and other CNS disorders.
Strategic Acquisition Accelerates Development
In the fourth quarter of 2025, Ever Supreme Bio Technology (搜索) announced the acquisition of 100% equity in Shine Out Bio Technology (搜索) through a share-exchange transaction, with the effective date of January 13, 2026. General Manager Mr. Huang Wen-Liang stated that the acquisition creates strong synergies between the two companies' technology platforms and therapeutic focus areas.
Under Taiwan's Regenerative Medicine Dual-Act framework, beginning January 1, 2026, regenerative products targeting life-threatening or severely disabling diseases may apply for a conditional five-year marketing authorization upon completion of Phase II clinical trials demonstrating safety and preliminary efficacy. This pathway significantly accelerates commercialization and promises improved therapeutic options for aging societies worldwide.